Novel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation
British Journal of Pharmacology · 2023
DOI: 10.1111/bph.16203 ↗At a glance
Journal article in British Journal of Pharmacology, 2023. Written by Henriette Andresen and 8 co-authors. Institution: Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway. Major MEDLINE topics: Atrial Natriuretic Factor, Guanylate Cyclase. Cited 4 times so far (Crossref); 62 references. The full text is freely available (open access, CC BY 4.0). Funded by: Wellcome Trust, British Heart Foundation, Anders Jahres Fond til Vitenskapens Fremme.
Abstract (original language)
Background and Purpose Guanylyl cyclase‐A (GC‐A), activated by endogenous atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), plays an important role in the regulation of cardiovascular and renal homeostasis and is an attractive drug target. Even though small molecule modulators allow oral administration and longer half‐life, drug targeting of GC‐A has so far been limited to peptides. Thus, in this study we aimed to develop small molecular activators of GC‐A. Experimental Approach Hits were identified through high‐throughput screening and optimized by in silico design. Cyclic GMP was measured in QBIHEK293A cells expressing GC‐A, GC‐B or chimerae of the two receptors using AlphaScreen technology. Binding assays were performed in membrane preparations or whole cells using 125 I‐ANP. Vasorelaxation was measured in aortic rings isolated from Wistar rats. Key Results We have identified small molecular allosteric enhancers of GC‐A, which enhanced ANP or BNP effects in cellular systems and ANP‐induced vasorelaxation in rat aortic rings. The mechanism of action appears novel and not mediated through previously described allosteric binding sites. In addition, the selectivity and activity depend on a single amino acid residue that differs between the two similar receptors GC‐A and GC‐B. Conclusion and Implications We describe a novel allosteric binding site on GC‐A, which can be targeted by small molecules to enhance ANP and BNP effects. These compounds will be valuable tools in further development and proof‐of‐concept of GC‐A enhancement for the potential use in cardiovascular therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway.
- Institute for Experimental Medical Research, University of Oslo and Oslo University Hospital, Oslo, Norway.
- William Harvey Research Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
ORCID profiles: Henriette Andresen, Cristina Pérez-Ternero, Adrian J Hobbs, Lincoln R Potter, Finn Olav Levy, Alessandro Cataliotti, Lise Román Moltzau
Funding
- Wellcome Trust
- British Heart Foundation
- Anders Jahres Fond til Vitenskapens Fremme
- Helse Sør-Øst RHF
- Nasjonalforeningen for Folkehelsen
- Norges Forskningsråd
- Universitetet i Oslo
Cite
APA
Andresen, H., Pérez-Ternero, C., Robinson, J., Dickey, D. M., Hobbs, A. J., Potter, L. R., Levy, F. O., Cataliotti, A., & Moltzau, L. R. (2023). Novel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation. British Journal of Pharmacology. https://doi.org/10.1111/bph.16203
Vancouver
Andresen H, Pérez-Ternero C, Robinson J, Dickey DM, Hobbs AJ, Potter LR, et al. Novel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation. British Journal of Pharmacology. 2023. doi:10.1111/bph.16203
BibTeX
@article{Andresen2023,
author = {Andresen, Henriette and Pérez-Ternero, Cristina and Robinson, Jerid and Dickey, Deborah M and Hobbs, Adrian J and Potter, Lincoln R and Levy, Finn Olav and Cataliotti, Alessandro and Moltzau, Lise Román},
title = {Novel enhancers of guanylyl cyclase‐A activity acting via allosteric modulation},
journal = {British Journal of Pharmacology},
year = {2023},
doi = {10.1111/bph.16203}
}
EUVIMED